AGIO
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals (AGIO) Q2 2026 earnings
Published Jul 30, 2026
AI summary
- Revenue $44.7M, up 259% from $12.5M a year ago.
- GAAP EPS −$1.69 missed the −$1.67 consensus by $0.02, up from −$1.93 a year ago.
- Agios reported second quarter 2026 revenue of $44.7 million, up from $12.5 million in the same period last year.
- The net loss for the quarter narrowed to $100.7 million compared to $112.0 million in the prior year.
- Revenue growth was driven by the U.S. commercial launch of AQVESME for thalassemia patients.
Results vs analyst consensus
Revenue
Reported
$44.7M
Consensus not captured before release
+259% YoY
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$1.69
Consensus −$1.67
Missed by $0.02GAAP EPS: −$1.69
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company will not advance tebapivat in lower-risk myelodysplastic syndromes or sickle cell disease.
- Research and development expenses increased due to a $25 million upfront payment for a new licensing agreement.
Read original report
Source: Agios Pharmaceuticals, Inc. press release · SEC Form 8-K exhibit 99.1